Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Katrina S. Pedersen, Patrick Grierson, Joel Picus, A. Craig Lockhart, Bruce J. Roth, Jingxia Liu, Ashley Morton, Emily Chan, Jesse Huffman, Chris Liang, Andrea Wang‐Gillam, Benjamin Tan
Topics & Concepts
EverolimusMedicineMucositisInternal medicineResponse Evaluation Criteria in Solid TumorsTyrosine-kinase inhibitorRenal cell carcinomaPlatelet-derived growth factor receptorOncologyPharmacologyProgressive diseaseGastroenterologyCancerChemotherapyReceptorGrowth factorRenal cell carcinoma treatmentPI3K/AKT/mTOR signaling in cancerPancreatic and Hepatic Oncology Research